Silence at the FDA: Biotechs Report Delays, Denied Meeting Requests Amid Staff Cuts

High turnover and staffing cuts at the U.S. Food and Drug Administration are causing ripple effects across the biotech industry. Companies report delayed reviews, postponed inspections, and, in some cases, outright denials of pre-IND meetings without explanation. For small and emerging biotechs, the lack of timely feedback complicates planning, raises costs, and heightens investor concerns. If unaddressed, the slowdown could shift innovation outside the United States and delay patient access to new therapies.

Introduction: A Denial Without Explanation

When one small biotech requested a pre-Investigational New Drug (pre-IND) meeting with the U.S. Food and Drug Administration (FDA) this year, the company expected what had long been standard practice: either approval of the meeting or constructive feedback explaining why it was denied. Instead, the request was refused with no rationale, no instructions for resubmission, and no communication at all beyond the denial notice.

For the company’s leadership, the silence was deafening. Without regulatory guidance, pipeline planning stalls. Investor confidence wavers. Time and money are wasted. And while a single unexplained denial might be an anomaly, multiple biotechs are reporting similar experiences. At the same time, venture capitalists and consultants describe a broader slowdown: reviews taking longer, inspection schedules slipping, and communication gaps widening.

The consensus explanation is straightforward, if troubling: high turnover and staffing cuts at the FDA have left critical functions under strain.

The Official Process vs. Current Reality

In theory, the process for engaging with the FDA at the pre-IND stage is clear, consistent, and tightly regulated. Under formal guidance, pre-IND meetings are classified as Type B meetings within the framework of the Prescription Drug User Fee Act (PDUFA). The agency commits to respond to a sponsor’s meeting request within 21 calendar days, notifying the company whether the request has been granted or denied. If granted, the meeting must be scheduled within 60 calendar days of the original request. Sponsors are also required to submit a complete briefing package — typically at least 30 days before the scheduled meeting — that provides background information on the program, outlines the scientific and regulatory context, and poses clearly framed questions across domains such as nonclinical pharmacology, toxicology, CMC strategy, and early clinical development plans.

The FDA generally provides preliminary written feedback on these briefing materials in advance of the meeting, often a few days beforehand, so that companies can determine whether the live meeting is still needed or whether written responses alone are sufficient. When meetings are held, they are typically one hour in duration and include the FDA review team as well as the sponsor’s development, clinical, and regulatory leads. The agency is then expected to provide formal meeting minutes within 30 days, ensuring that sponsors have an authoritative record of FDA positions that can be referenced in subsequent submissions. This highly structured process is designed to give companies a dependable regulatory checkpoint early in development, allowing them to optimize toxicology programs, anticipate CMC expectations, and align clinical trial design with agency standards before significant capital is committed.

Increasingly, however, industry feedback suggests that this orderly framework is breaking down. Many sponsors report that the 21-day deadline for grant or denial decisions is slipping, with weeks of silence before any response is issued. Even when meetings are granted, the 60-day scheduling target is often exceeded, leaving companies to recalibrate timelines for critical toxicology studies or first-in-human trials. Perhaps most troubling are instances in which meeting requests are denied without explanation. FDA guidance is explicit that denials should be accompanied by the reasons; for example, that the product is too early in development, that questions are insufficiently specific, or that the briefing package does not contain the required information. Yet several biotechs have reported receiving little or no rationale, leaving them uncertain about how to revise their submissions or when to reapply.

Even for those that do secure a meeting, the quality and timing of FDA feedback can be uneven. Sponsors sometimes receive preliminary responses only a day or two before the meeting, far too late to adjust their internal positions or decide whether to cancel the meeting in favor of written responses. In other cases, companies describe sessions in which FDA reviewers appear to be engaging with materials for the first time during the meeting itself, limiting the depth of discussion. Such scenarios diminish the value of the pre-IND interaction and undermine its role as a strategic checkpoint in development.

The consequences are particularly acute for smaller and emerging biotechs. Unlike large pharmaceutical companies with established regulatory affairs groups, many early-stage firms lack the in-house expertise to navigate ambiguity. For them, the pre-IND meeting is not merely a procedural step but a vital lifeline — often the first and only opportunity to secure clarity on data expectations, manufacturing standards, and trial design before advancing to costly nonclinical or clinical milestones. When these meetings are delayed, denied without feedback, or conducted without meaningful preparation, smaller companies are left to make high-stakes decisions in the dark.

The result is greater uncertainty, longer timelines, and higher costs at precisely the stage when resources are scarcest. For venture-backed biotechs already balancing investor expectations and cash burn, the erosion of predictability around pre-IND meetings adds a layer of regulatory risk that reverberates across development programs, financing strategies, and ultimately patient access to innovation.

Staffing Cuts and Institutional Strain

The slowdown in FDA responsiveness is not occurring in a vacuum. Reports from across the life sciences press point to a consistent driver: attrition and downsizing at unprecedented scale. Since late 2024, more than 3,500 positions across the FDA and the broader Department of Health and Human Services (HHS) have been eliminated, including seasoned reviewers, regulatory project managers, and administrative staff who form the backbone of day-to-day operations.¹

While the raw numbers are troubling enough, the true impact lies in the loss of institutional knowledge. Many of the individuals who departed were not only experienced reviewers but also subject matter experts in specialized therapeutic areas, such as gene therapy, cell therapy, or complex biologics. Their expertise often cannot be replaced quickly, and the new hires who eventually fill their roles face steep learning curves before they can review submissions with the same speed and confidence. Analysts warn that this knowledge gap is already creating bottlenecks in every review division, from oncology to rare diseases.

The consequences are highly visible in FDA’s field operations. Inspections — a cornerstone of regulatory oversight — were already under strain during the COVID-19 pandemic, when travel restrictions limited site visits and created a backlog of delayed or deferred inspections. Now, with the loss of support staff who handle travel logistics, document management, and compliance follow-up, even basic inspection coordination has become more difficult. Inspection capacity is again at risk of disruption, leaving manufacturers uncertain when their facilities will be audited or cleared.² For companies preparing to launch products or scale manufacturing, these delays can translate into significant financial and operational setbacks.

Early indicators of systemwide strain are also emerging in the medical device sector, which often serves as a bellwether for regulatory throughput. The number of novel device approvals and De Novo classifications has declined year over year, reflecting both slowed review times and reduced capacity to process complex applications.³ If these trends continue, they are likely to spill over into drug and biologics divisions, amplifying delays already being reported in pre-IND interactions and clinical trial authorizations.

Consultants and regulatory advisors confirm this picture on the ground. Firms like Veristat describe a pattern of “missed review deadlines” and “prolonged silences” from divisions once regarded as reliable and responsive.⁴ Whereas in the past sponsors could count on predictable turnaround times for regulatory correspondence, today they must often operate without clear feedback, leaving development teams in limbo.

Importantly, the strain is not only about workforce size but also about workforce quality. The FDA has long relied on reviewers with deep scientific and clinical backgrounds who understand both the technical nuances of submissions and the broader therapeutic context. When such individuals depart, the gap cannot be bridged immediately by new staff, no matter how talented. Even with aggressive hiring, it takes months, if not years, for new reviewers to gain the contextual knowledge required to evaluate complex data packages efficiently. During that ramp-up, throughput inevitably suffers.

The downstream effect is a regulatory environment where backlogs compound, timelines stretch, and sponsors shoulder greater uncertainty. For large pharmaceutical companies with dedicated regulatory affairs teams, these delays are an inconvenience; for smaller biotechs with limited cash runways, they can be existential. The FDA’s staffing crisis thus translates directly into heightened risk across the innovation ecosystem, with consequences that ripple from clinical trial sites to investors to patients awaiting new therapies.

Biotech Experiences on the Ground

For emerging companies, the effect of FDA slowdowns is stark and immediate. Executives facing these challenges are often reluctant to speak publicly, fearing that visible criticism of the agency might jeopardize future interactions or exacerbate delays. In off-the-record conversations, however, the frustration is palpable. What was once seen as a collaborative regulatory relationship now feels adversarial or, worse, indifferent. This erosion of trust between sponsors and the FDA creates a chilling effect: companies tread carefully, even when the stakes are existential.

Venture capitalists, who rely on predictable regulatory milestones to structure investments, have echoed these concerns. Slower or inconsistent FDA feedback directly increases perceived risk, making it more difficult for early-stage companies to secure financing. Investors accustomed to tying valuations to discrete regulatory achievements, such as a successful pre-IND meeting, IND clearance, or phase I trial initiation, now find those milestones harder to anticipate. As a result, valuations are falling and financing rounds are closing at smaller amounts or under less favorable terms.⁵ In some cases, VCs have advised portfolio companies to seek early regulatory engagement outside the United States or to build in longer timelines before capital raises, further complicating already fragile business models.

The financial implications are particularly acute because in biotech, “time is cash burn.” Every month of delay can mean millions of dollars in operating costs without corresponding progress toward value-creating milestones. For companies targeting rare diseases, where competitive windows are narrow, a denied or delayed meeting can mean losing first-mover advantage, allowing rivals to seize clinical leadership in the same indication. For companies working on cutting-edge modalities, such as cell and gene therapies, uncertainty around FDA expectations can result in costly over-preparation, with sponsors commissioning redundant toxicology studies or CMC work simply to hedge against unknown reviewer demands.

These dynamics create a vicious cycle: regulatory uncertainty erodes investor confidence, which reduces access to capital, which in turn makes companies less able to withstand further regulatory delays. For many small biotechs, the difference between survival and collapse may hinge on whether the FDA can deliver timely, transparent guidance.

The Global Competitive Dimension

One of the most troubling consequences of regulatory slowdown at the FDA is the growing possibility that innovation will migrate outside the United States. Historically, the United States has been the preferred launchpad for early-stage biotech development, in part because its regulatory framework combined scientific rigor with a degree of predictability and responsiveness that gave investors confidence. A successful pre-IND meeting or IND clearance was not only a scientific milestone but also a signal to capital markets that a program was de-risked and ready to advance.

That equation is now being challenged. Reuters has reported that some biotech firms are planning early-phase trials abroad to bypass uncertainty at home.⁶ Europe, particularly the United Kingdom and Germany, has positioned itself as an attractive alternative, with regulatory agencies that have expanded capacity for scientific advice meetings and accelerated trial authorizations. Canada, through Health Canada’s Biologic and Radiopharmaceutical Drugs Directorate, has gained attention for relatively streamlined early-phase engagement. In Asia, countries such as Singapore, South Korea, and Japan are also courting developers with clearer timelines for clinical trial initiation and, in some cases, more generous incentives for companies willing to conduct first-in-human studies locally.

For emerging companies under intense financial pressure, these international options are no longer theoretical. If the FDA cannot deliver timely feedback, sponsors may choose to initiate trials abroad, then seek U.S. alignment later once programs have matured. That shift carries clear risks, including the challenge of harmonizing trial data across regulatory jurisdictions, but it may be preferable to waiting indefinitely for U.S. guidance. For investors, the calculus is shifting as well: the global spread of innovation means that capital once concentrated in U.S.-based startups may follow development activity overseas.

If this trend accelerates, the United States risks eroding its long-standing leadership in biotech innovation. For decades, the FDA’s combination of rigor and responsiveness has anchored the global ecosystem, ensuring that the earliest and most important clinical milestones occurred on U.S. soil. This not only attracted capital but also fostered clusters of expertise in places like Boston, San Diego, and the Bay Area. With that compact now under strain, there is a real possibility that other regulatory agencies will step into the vacuum, positioning themselves as the new arbiters of early-stage innovation.

The consequences of such a shift would be profound. U.S. patients could face delayed access to cutting-edge therapies if first-in-human data are generated abroad and sponsors delay U.S. filings. The domestic talent pool could fragment as companies look to base operations in jurisdictions more closely aligned with their development timelines. And policymakers would find themselves confronting the loss of both scientific prestige and economic value in a sector that has long been a cornerstone of U.S. competitiveness.

For now, these are early warning signs rather than a full-scale exodus. But the message from industry is clear: if predictability and communication cannot be restored at the FDA, the gravitational pull of global alternatives will only grow stronger.

Policy Implications

The consequences of FDA slowdowns extend far beyond the operational challenges facing individual biotech companies. At stake is the agency’s dual role as both guardian of public safety and facilitator of biomedical innovation. When reviews, inspections, and meeting responses lag, the ripple effects are immediate and widespread: potentially lifesaving therapies are delayed in reaching patients; clinical trials stall, leaving participants in limbo; and public confidence in the FDA’s ability to keep pace with science and protect health begins to erode.

This erosion of confidence carries particular weight in an era when the FDA is tasked with reviewing increasingly complex modalities, from cell and gene therapies to RNA-based medicines and novel delivery platforms. Each of these requires specialized expertise, cross-disciplinary coordination, and often, case-by-case judgment. If the agency cannot provide timely and consistent guidance, sponsors may be forced either to over-invest in redundant studies or to proceed with uncertainty, neither of which serves patients or the public interest.

Policymakers are already paying attention. Several members of Congress have called for hearings into the scale and impact of FDA staffing cuts, framing the issue not only as an administrative challenge but also as a matter of national competitiveness.⁷ Some lawmakers have raised concerns that the United States could cede leadership in biomedical innovation if the FDA becomes a bottleneck rather than a partner. Others have suggested that if user fee revenues are not being deployed effectively to support review capacity, the underlying framework of PDUFA itself may require reassessment.

Industry groups, meanwhile, are pursuing a quieter but equally forceful campaign for greater transparency. Trade associations and coalitions of biotech CEOs are urging the FDA to publish granular performance metrics on key activities: the proportion of meeting requests granted or denied, the timeliness of responses relative to statutory deadlines, the average lag in inspection scheduling, and the frequency with which review divisions miss PDUFA goal dates. The argument is simple: if the agency cannot immediately restore capacity, it should at least give sponsors visibility into where the bottlenecks are, so they can plan accordingly.

Absent corrective action, the U.S. risks creating a two-tier regulatory system. Large pharmaceutical companies, with their dedicated regulatory affairs teams and financial reserves, may be able to weather delays, hiring external consultants and absorbing prolonged silences without jeopardizing survival. Smaller and mid-sized innovators, by contrast, operate on thin cash runways and depend on timely FDA interactions to unlock financing. If they cannot count on predictable feedback, many may be forced to scale back programs, delay entry into the clinic, or seek regulatory guidance abroad.

This analysis has focused primarily on the pharmaceutical and biotech industries, but it is important to remember that the FDA’s mandate extends far beyond drugs and biologics. The same staffing shortages and turnover are likely to affect food safety, medical devices, diagnostics, and tobacco regulation. Disruptions in these areas could carry equally serious implications for public health, consumer trust, and U.S. competitiveness, underscoring that the current crisis is not confined to one sector but threatens the agency’s ability to fulfill its full mission.

The danger is that innovation diversity will narrow at precisely the moment when the field most needs breadth. Cell therapies, gene therapies, RNA technologies, and other novel modalities demand a vibrant ecosystem of startups and academic spinouts to explore multiple approaches in parallel. If only the largest players can endure regulatory uncertainty, the pipeline of ideas will shrink, and patients may lose out on potentially transformative treatments.

In this sense, the FDA’s current struggles are not only a matter of bureaucratic efficiency but also of public health policy and economic strategy. Restoring transparency and responsiveness is essential to sustaining U.S. leadership in life sciences and to ensuring that patients continue to benefit from the full diversity of scientific innovation.

A Call for Transparency

The core complaint from biotechs is not simply that the FDA is slow, but that it is silent. In a well-functioning system, a denied pre-IND meeting would at least come with feedback: insufficient data, incomplete questions, or misaligned timing. Instead, some companies are left guessing.

Transparency is the remedy. Even amid staffing shortages, the agency can maintain trust by explaining its decisions, publishing aggregate performance metrics, and communicating clearly when timelines slip. Silence, by contrast, fosters speculation and undermines confidence.